Amoxicillin/Clavulanate

General

• Type: Antibiotic
• Dosage Forms: PO
• Common Trade Names: Augmentin

Adult Dosing

Infection, Bacterial:

• 500mg-875mg PO q12h

Pneumonia, community-acquired

• 2000mg ER PO q12h x 7-10 days

Pediatric Dosing

Infection, Bacterial:

• 25-45mg/kg PO divided q12h

Otitis Media:

• 90mg/kg/day PO divided q12h x 10 days

Special Populations

• Pregnancy: B
• Lactation: probably safe
• Renal Dosing
  • Adult: CrCl 10-30: give q12h, CrCl < 10, give q24h
  • Pediatric: CrCl 10-30: give q12h, CrCl < 10, give q24h
• Hepatic Dosing
  • Adult: none
  • Pediatric: none

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

• anaphylaxis
• steven johnson syndrome
• c.diff associated diarrhea
• hemolytic anemia
• leukopenia
• thrombocytopenia
• hepatitis
• seizures

Common

• diarrhea
• nausea
• rash
• pruritus
• vomiting
• glossitis
• transaminitis

Pharmacology

• Half-life: 1.1 hour
• Metabolism: Liver
• Excretion: urine
• Mechanism of Action:Bactericidal, inhibits cell wall mucopeptide synthesis, inhibits beta lactamases

Antibiotic Sensitivities

Group	Organism	Sensitivity
Gram Positive	Strep. Group A, B, C, G	S
	Strep. Pneumoniae	S
	Viridans strep	I
	Strep. anginosus gp	S
	Enterococcus faecalis	S
	Enterococcus faecium	S
	MSSA	S
	MRSA	R
	CA-MRSA	R
	Staph. Epidermidis	R
	C. jeikeium	R
	L. monocytogenes	X2
Gram Negatives	N. gonorrhoeae	S
	N. meningitidis	S
	Moraxella catarrhalis	S
	H. influenzae	S
	E. coli	S
	Klebsiella sp	S
	E. coli/Klebsiella ESBL+	R
	E coli/Klebsiella KPC+	R
	Enterobacter sp, AmpC neg	R
	Enterobacter sp, AmpC pos	R
	Serratia sp	R
	Serratia marcescens	X1
	Salmonella sp	S
	Shigella sp	S
	Proteus mirabilis	S
	Proteus vulgaris	S
	Providencia sp.	S
	Morganella sp.	I
	Citrobacter freundii	R
	Citrobacter diversus	R
	Citrobacter sp.	R
	Aeromonas sp	S
	Acinetobacter sp.	R
	Pseudomonas aeruginosa	R
	Burkholderia cepacia	R
	Stenotrophomonas maltophilia	R
	Yersinia enterocolitica	I
	Francisella tularensis	X1
	Brucella sp.	X1
	Legionella sp.	R
	Pasteurella multocida	S
	Haemophilus ducreyi	S
	Vibrio vulnificus	X1
Misc	Chlamydophila sp	R
	Mycoplasm pneumoniae	R
	Rickettsia sp	X1
	Mycobacterium avium	X1
Anaerobes	Actinomyces	S
	Bacteroides fragilis	S
	Prevotella melaninogenica	S
	Clostridium difficile	X1
	Clostridium (not difficile)	S
	Fusobacterium necrophorum	S
	Peptostreptococcus sp.	S

Key

• S susceptible/sensitive (usually)
• I intermediate (variably susceptible/resistant)
• R resistant (or not effective clinically)
• S+ synergistic with cell wall antibiotics
• U sensitive for UTI only (non systemic infection)
• X1 no data
• X2 active in vitro, but not used clinically
• X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
• X4 active in vitro, but not clinically effective for strep pneumonia

See Also

• Antibiotics (Main)

Source

Authors

Ross Donaldson, Babak Missaghi, Neil Young, Daniel Ostermayer